Literature DB >> 12102616

Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler.

Varsha Chavan1, Richard Dalby.   

Abstract

This study evaluated the effect of inhaled volume and simulated inspiratory flow rate ramps on fine particle output from dry powder inhalers (DPIs). A simple, robust system was developed to account for "rate of rise" (ramp) effects while maintaining a constant air flow through a multi-stage liquid impinger (MSLI), used for sizing the emitted particles. Ramps were programmed to reach 30 and 60 L/min over 100 milliseconds; 500 milliseconds; and 1, 2, and 3 seconds. Rotahaler was chosen as the test DPI. Testing was done with simulated inhalation volumes of 2 L and 4 L. Testing was also carried out using the USP apparatus 4. At 30 L/min, for a 2 L volume, the amount of drug exiting the device in fine particle fraction (FPF) increased from 2.33 microg to 6.04 microg from the 3-second ramp to the 100-millisecond ramp, with 11.64 microg in FPF for the USP (no ramp) method. At the same flow rate, for a 4 L volume, FPF increased from 2.23 microg to 8.45 microg, with 10.25 microg for the USP method. At 60 L/min, similar trends were observed. In general, at both flow rates, an increase in FPF was noted going from the shallowest to the steepest ramp. However, there were no significant differences in FPF when a 2 L inhaled volume was compared with a 4 L volume at each flow rate. Overall, these data suggest that the existing USP apparatus may overestimate FPF at flow rates lower than those recommended by the USP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102616      PMCID: PMC2751293          DOI: 10.1208/ps040206

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  17 in total

1.  Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7).

Authors:  M Igarashi; P W Finch; S A Aaronson
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

2.  Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family.

Authors:  M Yamasaki; A Miyake; S Tagashira; N Itoh
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

Review 3.  Functions of fibroblast growth factors in vertebrate development.

Authors:  M Goldfarb
Journal:  Cytokine Growth Factor Rev       Date:  1996-12       Impact factor: 7.638

4.  Renal hemodynamics and prostaglandin E2 excretion in a nonhuman primate model of septic shock.

Authors:  G L Schaer; M P Fink; B Chernow; S Ahmed; J E Parrillo
Journal:  Crit Care Med       Date:  1990-01       Impact factor: 7.598

5.  Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth.

Authors:  P W Finch; J S Rubin; T Miki; D Ron; S A Aaronson
Journal:  Science       Date:  1989-08-18       Impact factor: 47.728

6.  Structure and expression of human fibroblast growth factor-10.

Authors:  H Emoto; S Tagashira; M G Mattei; M Yamasaki; G Hashimoto; T Katsumata; T Negoro; M Nakatsuka; D Birnbaum; F Coulier; N Itoh
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

7.  Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression.

Authors:  H D Beer; C Florence; J Dammeier; L McGuire; S Werner; D R Duan
Journal:  Oncogene       Date:  1997-10       Impact factor: 9.867

8.  Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.

Authors:  H Mashimo; D C Wu; D K Podolsky; M C Fishman
Journal:  Science       Date:  1996-10-11       Impact factor: 47.728

9.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

10.  Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung.

Authors:  S Bellusci; J Grindley; H Emoto; N Itoh; B L Hogan
Journal:  Development       Date:  1997-12       Impact factor: 6.868

View more
  6 in total

1.  Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.

Authors:  Matthew S Coates; Hak-Kim Chan; David F Fletcher; Judy A Raper
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

2.  The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-17       Impact factor: 3.246

3.  Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.

Authors:  Gary P Martin; Christopher Marriott; Xian-Ming Zeng
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

4.  Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns.

Authors:  Daiki Hira; Tomoyuki Okuda; Daisuke Kito; Kazunori Ishizeki; Toyoko Okada; Hirokazu Okamoto
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

5.  Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.

Authors:  Catherine H Richardson; Marcel de Matas; Harold Hosker; Rahul Mukherjee; Ian Wong; Henry Chrystyn
Journal:  Pharm Res       Date:  2007-05-18       Impact factor: 4.200

6.  Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing.

Authors:  Jolyon P Mitchell; Jason A Suggett
Journal:  AAPS PharmSciTech       Date:  2014-06-04       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.